The loss of vital cells within healthy tissues contributes to the development, progression and
treatment outcomes of many human disorders, including neurological and infectious …

Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-
family interactions makes it challenging to predict cell fate via standard molecular biology …

Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL2
inhibitor, may allow targeting of both BCL2 and BCL-XL without dose-limiting …

Abstract Models that recapitulate the complexity of human tumors are urgently needed to
develop more effective cancer therapies. We report a bank of human patient-derived …

Treatment-persistent residual tumors impede curative cancer therapy. To understand this
cancer cell state we generated models of treatment persistence that simulate the residual …

Suppression of apoptosis by expression of antiapoptotic BCL2 family members is a hallmark
of acute myeloblastic leukemia (AML). Induced myeloid leukemia cell differentiation protein …

The essential job of precision medicine is to match the right drugs to the right patients. In
cancer, precision medicine has been nearly synonymous with genomics. However, sobering …

The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently
transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically …

Truncating mutations in the terminal exon of protein phosphatase Mg2+/Mn2+ 1D (PPM1D)
have been identified in clonal hematopoiesis and myeloid neoplasms, with a striking …

Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical
problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) models …